March 5, 2024

CAR T-Cell Therapy Market Size to Grow US$ 6.43 Billion By 2032

The global CAR T-cell therapy market size was approximate at US$ 2.19  billion in 2022 and is anticipated to grow US$ 6.43  billion by 2032, registering a compound annual growth rate of 11.37% from 2023 to 2032.

CAR T Cell Therapy Market Size 2023 To 2032 Precedence Statistics

The CAR T-cell therapy market report covering various industry elements and growth trends helpful for predicting the market’s future.

The study provides a strong base for the CAR T-cell therapy market to be segmented into different segments. In fact, the study also covers the maximum market share during the assessment period by 2032.

This study is based on the partners that are highly competitive, key players as well as their market revenue in the forecast years of 2023 g0066ztr to 2032. There is also a strong focus on product revenues, sales, product categories and even the products that are experiencing the most traction. In this manner, the CAR T-cell therapy report also speaks about the effectiveness of this market along with its growth during the forecast period of 2030. Other major attributes of the CAR T-cell therapy market have been studied and analysed across many developments.

Request a Sample Copy of This Report @ https://www.precedenceresearch.com/sample/2545

CAR T-Cell Therapy Market Report Scope

Report Coverage Details
Market Size in 2023 USD 2.44 Billion
Market Size by 2032 USD 6.43 Billion
Growth Rate from 2023 to 2032 CAGR of 11.37%
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Drug Type, By Indication and By End User

Also read: Newborn Eye Imaging Systems Market Size to Grow US$ 390.74 Billion By 2032

Research Approach

The comprehensive report on the global CAR T-cell therapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. Following this, the report provides detailed explanation of objectives of this study and laid down by accredited agencies in the purview of research in the global CAR T-cell therapy market.

It is followed by market introduction, market dynamics, and an overview of the global market, which includes analysis of market drivers, restraints, and trends pertaining to the global market. Furthermore, Y-o-Y growth analysis with elaborated insights has been provided in order to understand the Y-o-Y growth trend of the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Key Players

  • Kolon TissueGene, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Kolon TissueGene, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • MEDIPOST
  • PHARMICELL Co., Ltd.
  • ANTEROGEN. CO., LTD
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Gilead Sciences, Inc.
  • Curocell, Inc.
  • JW Therapeutics (Shanghai) Co., Ltd.
  • Stempeutics Research PVT LTD

CAR T-Cell Therapy Market Segmentations

By Drug Type

  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Others

By Indication

  • Lymphoma
  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia (CLL)
  • Multiple Myeloma (MM)
  • Others

By End User

  • Hospitals
  • Cancer Treatment Centers

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on CAR T-Cell Therapy Market 

5.1. COVID-19 Landscape: CAR T-Cell Therapy Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global CAR T-Cell Therapy Market, By Drug Type

8.1. CAR T-Cell Therapy Market, by Drug Type, 2022-2032

8.1.1 Axicabtagene Ciloleucel

8.1.1.1. Market Revenue and Forecast (2022-2032)

8.1.2. Tisagenlecleucel

8.1.2.1. Market Revenue and Forecast (2022-2032)

8.1.3. Brexucabtagene Autoleucel

8.1.3.1. Market Revenue and Forecast (2022-2032)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2022-2032)

Chapter 9. Global CAR T-Cell Therapy Market, By Indication

9.1. CAR T-Cell Therapy Market, by Indication, 2022-2032

9.1.1. Lymphoma

9.1.1.1. Market Revenue and Forecast (2022-2032)

9.1.2. Acute Lymphocytic Leukemia

9.1.2.1. Market Revenue and Forecast (2022-2032)

9.1.3. Chronic Lymphocytic Leukemia (CLL)

9.1.3.1. Market Revenue and Forecast (2022-2032)

9.1.4. Multiple Myeloma (MM)

9.1.4.1. Market Revenue and Forecast (2022-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2022-2032)

Chapter 10. Global CAR T-Cell Therapy Market, By End User 

10.1. CAR T-Cell Therapy Market, by End User, 2022-2032

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2022-2032)

10.1.2. Cancer Treatment Centers

10.1.2.1. Market Revenue and Forecast (2022-2032)

Chapter 11. Global CAR T-Cell Therapy Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.1.2. Market Revenue and Forecast, by Indication (2022-2032)

11.1.3. Market Revenue and Forecast, by End User (2022-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.1.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.1.4.3. Market Revenue and Forecast, by End User (2022-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.1.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.1.5.3. Market Revenue and Forecast, by End User (2022-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.2.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.3. Market Revenue and Forecast, by End User (2022-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.2.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.4.3. Market Revenue and Forecast, by End User (2022-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.2.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.5.3. Market Revenue and Forecast, by End User (2022-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.2.6.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.6.3. Market Revenue and Forecast, by End User (2022-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.2.7.2. Market Revenue and Forecast, by Indication (2022-2032)

11.2.7.3. Market Revenue and Forecast, by End User (2022-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.3.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.3. Market Revenue and Forecast, by End User (2022-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.3.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.4.3. Market Revenue and Forecast, by End User (2022-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.3.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.5.3. Market Revenue and Forecast, by End User (2022-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.3.6.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.6.3. Market Revenue and Forecast, by End User (2022-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.3.7.2. Market Revenue and Forecast, by Indication (2022-2032)

11.3.7.3. Market Revenue and Forecast, by End User (2022-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.3. Market Revenue and Forecast, by End User (2022-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.4.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.4.3. Market Revenue and Forecast, by End User (2022-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.4.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.5.3. Market Revenue and Forecast, by End User (2022-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.4.6.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.6.3. Market Revenue and Forecast, by End User (2022-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.4.7.2. Market Revenue and Forecast, by Indication (2022-2032)

11.4.7.3. Market Revenue and Forecast, by End User (2022-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.5.3. Market Revenue and Forecast, by End User (2022-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.5.4.2. Market Revenue and Forecast, by Indication (2022-2032)

11.5.4.3. Market Revenue and Forecast, by End User (2022-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)

11.5.5.2. Market Revenue and Forecast, by Indication (2022-2032)

11.5.5.3. Market Revenue and Forecast, by End User (2022-2032)

Chapter 12. Company Profiles

12.1. Kolon TissueGene, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. JCR Pharmaceuticals Co., Ltd.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Kolon TissueGene, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. JCR Pharmaceuticals Co., Ltd.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. MEDIPOST

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. PHARMICELL Co., Ltd.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. ANTEROGEN. CO., LTD

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Bristol-Myers Squibb Company

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Novartis AG

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Gilead Sciences, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Why should you invest in this report?

If you are aiming to enter the global CAR T-cell therapy market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for CAR T-cell therapy are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2023-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com

 

Prathamesh

I have completed my education in Bachelors in Computer Application. A focused learner having a keen interest in the field of digital marketing, SEO, SMM, and Google Analytics enthusiastic to learn new things along with building leadership skills.

View all posts by Prathamesh →

Leave a Reply

Your email address will not be published. Required fields are marked *